Management of cutaneous vascular complications in systemic scleroderma: Experience from the German network

Rheumatology International

Volumn 28, Issue 10, 2008, Pages 1023-1029

  Herrgott, Ilka ^a   Riemekasten, Gabriela ^b   Hunzelmann, Nicolas ^c   Sunderkötter, Cord ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Diagnostic; Raynaud's phenomenon; Scleroderma network; Systemic sclerosis; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ILOPROST; NIFEDIPINE; NITRATE; PENTOXIFYLLINE; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

ALGORITHM; ARTICLE; CONSENSUS; DIAGNOSTIC APPROACH ROUTE; DIGITAL SUBTRACTION ANGIOGRAPHY; DIGITAL ULCER; DOPPLER ECHOGRAPHY; DOPPLER FLOWMETER; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EVALUATION; GERMANY; MAGNETIC RESONANCE ANGIOGRAPHY; MICROSCOPY; OSCILLOMETRY; PHYSIOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RAYNAUD PHENOMENON; REGISTER; SKIN BLOOD VESSEL DISORDER; SKIN ULCER; SYSTEMIC SCLEROSIS;

CALCIUM CHANNEL BLOCKERS; GERMANY; HEALTH CARE SURVEYS; HUMANS; PROFESSIONAL PRACTICE; PROSTAGLANDINS I; QUESTIONNAIRES; RAYNAUD DISEASE; REGISTRIES; SCLERODERMA, SYSTEMIC; SKIN; SKIN ULCER; VASODILATOR AGENTS;

EID: 47249141706     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0556-1     Document Type: Article

References (22)

1. LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22(4):675-694
2. Block JA, Sequeira W (2001) Raynaud's phenomenon. Lancet 357(9273):2042-2048
3. LeRoy EC (1989) The pathogenesis of systemic sclerosis. Clin Exp Rheumatol 7(Suppl 3):S135-S137
4. Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F et al (1999) Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum 42(2):306-310
5. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 44(8):1841-1847
6. Riemekasten G, Sunderkötter C (2006) Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii49-iii51
7. Sunderkötter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii33-iii35
8. Planchon B, de Faucal P, Essboui S, Grolleau JY (1986) A quantitative test for measuring reactivity to cold by the digital plethysmograph technique: application to 66 control subjects and 65 patients with Raynaud's phenomenon. Angiology 37(6):433-439
9. Pistorius MA, Planchon B, de Faucal P (1994) Plethysmographic cold test for diagnosis and evaluation of the severity of Raynaud's phenomenon. Validation of the method by factorial analysis of correspondences in 541 patients. Int Angiol 13(1):10-14
10. Bukhari M, Herrick AL, Moore T, Manning J, Jayson MI (1996) Increased nailfold capillary dimensions in primary Raynaud's phenomenon, systemic sclerosis. Br J Rheumatol 35(11):1127-1131
11. Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158(6):595-600
12. Sarkozi J, Bookman AA, Lee P, Keystone EC, Fritzler MJ (1987) Significance of anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med 83(5):893-398
13. Hummers LK, Wigley FM (2003) Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29(2):293-313
14. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66(6):754-763
15. Merkel PA, Herln K, Martin RW, Anderson JJ, Mayes MD, Bell P et al (2002) Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 46(9):2410-2420
16. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19(9):1407-1414
17. Veale DJ, Collidge TA, Belch JJ (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54(10):853-855
18. Taylor MH, McFadden JA, Bolster MB, Silver RM (2002) Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 29(1):102-106
19. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000953
20. Sunderkötter C, Riemekasten G (2006) Raynaud phänomen in der Dermatologie: Teil 2: Therapie. Hautarzt 57:927-938
21. Distler M, Distler J, Ciurea A, Kyburz D, Muller-Ladner U, Reich K et al (2006) Evidence-based therapy of Raynaud's syndrome. Z Rheumatol 65(4):285-289
22. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000954